PACB vs VVOS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PACB Captures Institutional Edge (2โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pacific Biosciences of California, Inc. (PACB) driven by superior Momentum & Technical, Options & Structure while VVOS counters with relative strength in Growth & Margin. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus VVOS at N/M Forward P/E and -107.9% operating margin (+34.9% YoY). In options structure, PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro) against VVOS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PACB Revenue | VVOS Revenue | PACB Op. Margin | VVOS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $80M | N/A | -128.4% | N/A | PACB |
| FY2019 | $90M | $10M | -110.6% | -92.8% | VVOS |
| FY2020 | $80M | $10M | -132.3% | -92.1% | VVOS |
| FY2021 | $130M | $20M | -161.2% | -120.7% | VVOS |
| FY2022 | $130M | $20M | -239.4% | -156.2% | VVOS |
| FY2023 | $200M | $10M | -166.8% | -125.3% | VVOS |
| FY2024 | $150M | $20M | -308.0% | -74.3% | VVOS |
| FY2025 | $160M | $20M | -346.2% | -114.1% | VVOS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PACB | VVOS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $549.5M | $1.9M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +5.5% | +34.9% | Higher Growth | VVOS |
| Operating Margin (TTM) Profitability | -333.0% | -107.9% | Higher Margin | VVOS |
| Net Profit Margin Profitability | -81.3% | -121.8% | Higher Margin | PACB |
| Return on Equity (ROE) Capital Efficiency | -929.3% | -8585.3% | Higher ROE | PACB |
| 52-Week Range Position Momentum | 24% ($1โ$3) | 0% ($0โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 2.25ฮฒ ยท 104% Vol | 1.70ฮฒ ยท 111% Vol | Lower Realized Risk | PACB |
| Unified Institutional Score Composite Signal | 50.1 / 100 (HOLD) | 36.4 / 100 (SELL) | Higher Composite | PACB |